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Background: Oncologists use Eastern Cooperative Oncology Group (ECOG) performance score to assess
patients' performance status (PS) and guide treatment decisions, but patients may not necessarily agree
on their scores. We compared PS scores assessed by patients with non-small-cell lung cancer (NSCLC) to
those of their medical oncologists to explore concordance and whether any discrepancy may have im-
plications on treatment and survival prediction.
Methods: NSCLC patients self-assessed their PS scores using the Patient-Generated Subjective Global
Assessment tool prior to chemotherapy. Kappa was used to assess agreement of ECOG scores between
patients and oncologists. Survival was calculated from date of chemotherapy using Kaplan Meier method.
Results: A total of 79 patients (median age 63 years, 87% stages IIIB/IV) were included. PS scores differed
in 34 (43%) cases. The inter-rater reliability between patients and their oncologists was Kappa¼0.35
(po0.001). In 31/34 (91%) of cases where the physicians and patients did not agree, physicians were
more optimistic in their PS rating. If only patient PS scores were used, 11 patients (14%) would be deemed
unﬁt for chemotherapy (ECOGZ3) and 21 patients (27%) would be excluded from most chemotherapy
trials (ECOGZ2). ECOG (0 versus 40) irrespective of assessor was predictive of survival (p¼0.017–
0.023).
Conclusions: There was only fair agreement in PS scores assessed by NSCLC patients and oncologists,
with patient scores usually poorer. A number of patients would have excluded themselves from ther-
apeutic interventions including clinical trials based on their PS rating.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Assessment of function and self-care is integral in evaluating
the impact of disease and its treatment on a cancer patient. The
Eastern Cooperative Oncology Group (ECOG) performance status
(PS) scoring system (Table 1) is a simple tool that is used in ev-
eryday practice to rate a patient's PS [1]. The extant literature has
shown ECOG PS to correlate with response to treatment, quality of
life and survival in a number of malignancies including non-smallLtd. This is an open access article u
.gov.au (A. Malalasekera).cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast
cancer and ovarian cancer [2–7].
Physicians' assessment of PS is an important part of the deci-
sion-making process regarding a patients' suitability for treat-
ments that may inﬂuence survival. Patients with metastatic NSCLC
are generally considered not suitable for chemotherapy if their
ECOG PS was greater than two. In the clinical trial setting, the
eligibility criteria is often more stringent, with patients requiring a
PS of one or less to be eligible for many chemotherapy trials. Both
physicians and patients’ assessment of ECOG PS have been found
to be predictive of survival in NSCLC and SCLC, as well as for dis-
ease stage in NSCLC. However, patients and physicians do not
necessarily agree in their rating of PS scores [8,9]. Ando et al.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Eastern Cooperative Oncology Group (ECOG) Performance Status scoring system with corresponding Patient-Generated Subjective Global Assessment (PGSGA) description.
ECOG Performance Status Description Corresponding Patient-Generated Subjective Global
Assessment (PGSGA) description
0 Fully active, able to carry out all pre-disease function without restriction. Normal with no limitations.
1 Restricted in physically strenuous activity but ambulatory and able to carry out
work of a light or sedentary nature (eg., light house work, ofﬁce work).
Not my normal self, but able to be up and about with
fairly normal activities.
2 Ambulatory and capable of all self-care but unable to carry out any work activ-
ities. Up and abouto50% waking hours.
Not feeling up to most things, but in bed or chair less
than half the day.
3 Capable of only limited self-care. Conﬁned to bed or chair 450% waking hours. Able to do little activity and spend most of the day in
bed or chair.
4 Completely disabled. Cannot carry out any activities of self-care. Fully conﬁned to
bed or chair.
Pretty much bed-ridden, rarely out of bed.
5 Dead
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tended to be more ‘optimistic’ than the patient-assessed scores [9].
Another study found that both physician and patient-assessed PS
was signiﬁcant at predicting survival in patients with a primary
lung cancer, with physician-assessed scores being marginally
better, even after adjusting for stage or gender [8].
The current study aims to determine the agreement between
ECOG PS scores by patients with NSCLC and their treating oncol-
ogist, and to assess if any difference in scores has potential im-
plications for treatment and survival prediction.Table 2
Eastern Cooperative Oncology Group (ECOG) performance status scores as assessed
by physician and patient.
ECOG PS Score Physician
0 1 2 3 Total
PATIENT 0 21 3 0 0 24
1 13 21 0 0 34
2 2 5 3 0 10
3 3 2 6 0 11
4 0 0 0 0 0
Total 39 31 9 79
Italicized and bold numbers reﬂect the numbers of cases where there was con-
cordance between the ECOG PS scores between physician and patient.2. Materials and methods
Between February 2007 and January 2011, chemotherapy-naive
patients with a pathologic diagnosis of NSCLC who were scheduled
to start chemotherapy were invited to participate in two in-
vestigator-initiated studies, one evaluating Inter-Ethnic Differ-
ences between Caucasian and Asian patients in pharmacokinetics
and toxicity from chemotherapy, and the other evaluating the
nutritional status of patients at Concord Cancer Centre, Sydney,
Australia [10,11]. Both studies were approved by the Concord Re-
patriation General Hospital Human Research Ethics Committee
and all patients provided written informed consent.
Patients self-assessed their physical and functional status as
part of their nutritional status evaluation using the Patient-Gen-
erated Subjective Global Assessment (PGSGA) questionnaire (Ta-
ble 1), prior to commencement of chemotherapy. The physician
assessed the patient's ECOG PS score using the conventional
scoring system detailed in Table 1, as per routine practice. Both
physician and patient were blinded to the other's PS score. The
medical oncologist recommended patient treatment including
radiotherapy, chemotherapy, surgery and/or supportive care based
on stage, subtype and patient's functional status.
Simple Kappa coefﬁcient was used to assess agreement of PS
scores between patients and oncologists. The PS scores were ca-
tegorized into 0 and 40. We did not stratify the results according
to single ECOG values as patients with physician ECOG PS rating of
Z2 were few in numbers and not deemed ﬁt for a platinum
doublet. Survival was calculated from the date of chemotherapy
until the date of death or the last recorded hospital encounter.
Actuarial survival was calculated using Kaplan Meier methods and
reported as cumulative survival (95% Conﬁdence Interval [95%CI]).
Log-rank test was used to determine if the PS score was associated
with survival. Statistical analyses were performed using the Sta-
tistical Product and Service Solutions (SPSS)(Version 21).
3. Results
A total of 79 chemotherapy-naïve patients with NSCLC were
included in this study. The median age was 63 years (range 38–81years) with the majority of patients being male (68%). Most pa-
tients (87%) had stage IIIB or IV disease and 11% had stage IIIA; 82%
were classiﬁed as non-squamous histology. Fifty nine patients
(75%) were Caucasian and 20 (25%) were of Asian ethnicity.4. Discrepancies and concordance in scoring between patients
and their physicians
PS scores differed in 34 (43%) cases (Table 2). The inter-rater
reliability between patients and their medical oncologists was
Kappa¼0.35 (po0.001).
In 31 out of 34 (91%) cases where the physicians and patients
did not agree, physicians were more optimistic in their ECOG PS
rating. Six out of nine (67%) patients rated as ECOG PS 2 by their
oncologist, self-rated their ECOG PS as 3.5. Correlation of ECOG PS score with survival
Irrespective of the assessor, ECOG PS (0 versus 40) was pre-
dictive of survival, with 18.7 versus 12.1 months (p¼0.023) and
17.4 versus 11.1 months (p¼0.017) for patient and oncologist-as-
sessed ECOG PS respectively (Figs. 1 and 2).
In a post hoc subgroup analysis, 39 patients whose oncologists
assessed their scores as ECOG PS 0, but who self-rated their PS as
40, had a trend for shorter median survival compared to those
patients who self-rated their scores as ECOG PS 0 (16.7 months
versus 18.2 months respectively, p¼0.31) (Fig. 3).6. Potential treatment implications of the discordance in ECOG
assessment
If only patient PS scores were used, 11 patients (14%) would be
deemed unﬁt for chemotherapy (ECOGZ3) and 21 patients (27%)
Fig. 1. Kaplan–Meier graph showing cumulative survival of 79 patients according
to their self-rated ECOG score. (Units of x axis¼months).
Fig. 2. Kaplan–Meier graph showing cumulative survival of 79 patients according
to their Oncologist's ECOG rating. (Units of x axis¼months).
Fig. 3. Kaplan–Meier graph showing cumulative survival of 39 patients rated by
their oncologists as ECOG 0, but self-rated as 40 (Units of x axis¼months).
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PSZ2).7. Discussion
Karnofsky and colleagues described the ﬁrst PS score in 1948
[12]. This score is usually described in standard intervals of 10
from 100 (normal function) to 0 (dead). In 1960, the 5-point ECOG
PS was introduced as a simpler and faster screening tool fordetermining patients' PS [1]. The ECOG PS is based primarily on
physical activity, derived from information received from the pa-
tient, carers and clinician assessment. Although physician-as-
sessed ECOG PS is the standard common measure of ﬁtness to
determine suitability to receive chemotherapy or participate in
clinical trials, it may not correlate with actual physical activity and
functional status of patients. Therefore we sought to determine if
there is a discrepancy between the PS score between NSCLC pa-
tients and their oncologist.
We found there was only a fair agreement in ECOG PS assessed
by NSCLC patients and their oncologists, with patient scores
usually indicating poorer ECOG PS (Kappa¼0.35; po0.001). This
is consistent with the existing literature, where agreement be-
tween lung cancer patients and their doctors is fair to moderate,
with weighted Kappa scores between 0.41 and 0.45 [8,13]. Ando
et al. found agreement to be signiﬁcantly less between female
patients and their oncologists at 37.2% compared to 54% between
male patients and their oncologists (p¼0.037) [9].
In our study, the major discrepancy in scoring was in those
patients who self-rated their ECOG PS as 3, whereas their physi-
cians had rated these patients as ECOG PS 2. The reasons for the
generally poorer assessment of PS by patients themselves are not
clear from the scope of this study. However, several hypotheses
could be made. Firstly, 25% of patients were from an Asian back-
ground in our study, where English was not their ﬁrst language.
Interpreters were used as required but it is possible that there may
have been a language barrier affecting interpretation of ECOG PS
ratings. The ethnicity breakdown of patient cohorts in similar
studies is not known, however it is interesting to note the higher
level of concordance between patients' and physicians' ECOG PS
scores in Blagden et al.'s study in Cambridge, United Kingdom
(Kappa 0.45) [8].
Secondly, patients may attach a more pessimistic association
with a cancer diagnosis, reﬂecting a poorer self-assessment of
performance status. In Lilenbaum et al.'s study of 503 lung cancer
patients, prevalence of poor ECOG PS (deﬁned as ECOG PS of two
to four) among patients was 34% when estimated by healthcare
providers and 48% when estimated by patients themselves [13].
Patients in the study by Blagdan et al. were unaware of their di-
agnosis prior to self-rating their ECOG PS [8]. They showed pa-
tient-rated scores had higher concordance with their oncologists
(weighted Kappa¼0.45), compared to the concordance rate in our
study. This could potentially be explained by the fact that our
patients and their oncologists were already aware of their diag-
nosis of primary lung cancer prior to scoring their PS using the
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Additionally, the performance rating system in the PGSGA used
by patients in our study alluded to aspects of emotional wellbeing,
such as “Not feeling up to most things” (for a corresponding ECOG
PS of 2) and “Not my normal self” (for ECOG PS of 1). Chan et al.
hypothesised that a discrepancy between patient-rated and phy-
sician-rated ECOG PS scores may signify a greater burden of psy-
chological distress in patients [14]. They propose that the ECOG PS
rating system be used as a surrogate screening instrument for
hitherto undiagnosed anxiety and/or depression, which may im-
pact patient wellbeing and treatment-related outcomes. This
would equip physicians not trained in full psychological assess-
ment with a simpler tool for screening for psychological illnesses.
Indeed, Hopwood and Stevens showed that 33% patients with in-
operable lung cancer had self-reported depressive illness before
treatment [15], a co-morbidity which warrants early intervention
in the course of palliation. However, we did not have any objective
measurement of psychological wellbeing of patients in our study,
which may have helped to elucidate reasons for disagreement in
scores.
Given our ﬁnding, it raises the question whether physician's
assessment is accurate enough, as patients' self-rating may depict
their functional status more accurately. The oncologist only as-
sesses the patient based on contact for a short period of time
whereas the patient is more aware of their day-to day functional
limitations. The beneﬁt of chemotherapy for NSCLC patients does
not appear to extend beyond those patients with an ECOG PSZ3
[16,17], but It is unknown if the same applies when the physician
rates the PS as 2 but the patients self rate their PS as 3. In our
study, if patient ECOG PS scores were used, 14% of the patients
would be deemed unﬁt for chemotherapy (ECOG PSZ3) and 27%
of the patients would be excluded from the majority of active
treatment trials (ECOG PSZ2). However, it is unclear whether
overall patient outcome would improve using patient's own as-
sessment of their PS. We believe that this warrants further study.
A number of studies have found that a poor ECOG PS is a ne-
gative prognostic factor for patients with cancer [18,19]. In studies
where survival has been quantiﬁed, the physicians are the ob-
servers who assess the PS scores [20]. This raises a further issue
whether this discrepancy in PS assessment would impact on the
survival prediction. In our study, ECOG PS irrespective of assessor
was predictive of survival. However in a subgroup analysis, pa-
tients whose oncologists rated them as having excellent PS but
who self-rated as 40, corresponded with a shorter median sur-
vival by 1.5 months, compared to those patients who self-rated as
ECOG PS 0 (p¼0.31). Although this result did not reach statistical
signiﬁcance, possibly due to the small number of patients in-
volved, patients who self-rate their ECOG PS score as 40 may
have worse survival despite their oncologist's more optimistic
scoring. Our ﬁndings mirror the results of Johansen et al., where
patients tended to have a worse outcome if they assessed their PS
score as 41 while their physicians more optimistically assessed it
as¼1 [21]. However, there is a report showing that the oncologist
assessed PS more closely ﬁts observed survival data, suggesting
that the prognostic value of PS assessments by patients does not
exceed that by their oncologists [9]. In view of the conﬂicting re-
sults in the literature, this should be studied further.
There are limitations in our study. Resource limitations pre-
vented us from having two physicians assess ECOG PS in each
patient to more effectively study interobserver reproducibility.
Due to our small sample size, we were unable to assess for a
survival difference between patient-rated and physician-rated
scores of ECOG PS 3. Furthermore, the measurements of ECOG PS
in this study were technically different, as patients assessed their
PS based on the PGSGA and oncologists used the World Health
Organisation (WHO) deﬁned ECOG criteria. This may impact thelevel of agreement between the groups' scores and introduce po-
tential bias. This study is also limited by selection bias because all
patients invited to participate had already been medically assessed
as being suitable for chemotherapy.
In conclusion, this study highlights that while ECOG PS in-
dependently rated by patients and their oncologists were pre-
dictive of overall survival, there was only fair inter-rater level of
agreement. Where physicians are optimistic in their ratings, pa-
tients may be more discerning when self-rating PS. We need to
further explore reasons behind discrepancies of scores during our
clinical appraisal and consider if they reﬂect important insights
into patients’ psychological wellbeing and quality of life.8. Clinical practice points
Use of the Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) scoring system is often used in practice to
assess a patient's suitability to receive chemotherapy or participate
in clinical trials. Current literature has shown ECOG PS, as assessed
by physicians, to correlate with response to treatment, quality of
life and survival in a number of malignancies. This study shows
that there was only mild agreement in performance status as-
sessed by Non Small Cell Lung Cancer patients and their oncolo-
gists, with patient scores usually poorer. Patients' self-rating of
functional status may reﬂect a degree of psychological burden.
ECOG PS irrespective of assessor was predictive of survival. How-
ever, in a subgroup analysis, patients whose oncologists rated
them as having excellent PS but who self-rated as 40, corre-
sponded with a shorter median survival by 1.5 months, compared
to those patients who self-rated as ECOG PS 0 (p¼0.31). Patients
who self-rate their ECOG PS score as 40 may have worse survival
despite their oncologist's more optimistic scoring.Conﬂicts of interest
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